In December of last year, Neogap announced that the company’s patent application for the European market was being prepared for approval through a “Notice of Allowance”. Neogap has now obtained final approval from the European Patent Office for their pioneering approach to multiplying T-cells outside the body using their EpiTCer® technology and the production of tumor-specific T-cells. The patent, valid until 2038, ensures that Neogap’s EpiTCer® technology is patent protected across various markets.
“We are pleased that Neogap has been granted this patent in Europe. Our continuous evaluation of intellectual property rights ensures the protection of our unique cancer therapies. Our focus is to develop our treatments for personalized immunotherapy, to increase survival rates, and improve the quality of life for cancer patients,” says Samuel Svensson, CEO of Neogap.